GALECTIN THERAPEUTICS INC 4

Accession 0000914062-14-000098

$GALTCIK 0001133416operating

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 5:06 PM ET

Size

24.4 KB

Accession

0000914062-14-000098

Form 4

Period: 2014-01-31

Director

Transactions

Exercise/Conversion
Common Stock
2014-01-31$1.20/sh+83,334$100,001→ 86,937 total
Exercise/Conversion
Stock Option (right to buy)
2014-01-31−667→ 0 total
Exercise: $0.72From: 2009-02-08Exp: 2014-02-08→ Common Stock (667 underlying)
Exercise/Conversion
Common Stock
2014-01-31$0.72/sh+667$480→ 3,603 total
Exercise/Conversion
Common Stock
2014-01-31$6.48/sh+9,260$60,005→ 96,197 total
Exercise/Conversion
Common Stock
2014-01-31$3.59/sh+6,269$22,506→ 110,941 total
Tax Payment
Common Stock
2014-01-31$13.71/sh−17,722$242,969→ 93,219 total
Exercise/Conversion
Stock Option (right to buy)
2014-01-31−9,260→ 0 total
Exercise: $6.48Exp: 2016-03-24→ Common Stock (9,260 underlying)
Exercise/Conversion
Common Stock
2014-01-31$7.08/sh+8,475$60,003→ 104,672 total
Exercise/Conversion
Stock Option (right to buy)
2014-01-31−83,334→ 0 total
Exercise: $1.20Exp: 2014-02-25→ Common Stock (83,334 underlying)
Exercise/Conversion
Stock Option (right to buy)
2014-01-31−8,475→ 0 total
Exercise: $7.08Exp: 2021-06-28→ Common Stock (8,475 underlying)
Exercise/Conversion
Stock Option (right to buy)
2014-01-31−6,269→ 10,445 total
Exercise: $3.59Exp: 2023-03-28→ Common Stock (6,269 underlying)

Footnotes (9)

[F1]This option was previously reported as covering 4,000 shares at an exercise price of $0.12 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
[F2]Stock Option grant, vested as follows: (i) 50% on February 25, 2010; (ii) 25% on May 25, 2010; (iii) 12.5% on August 25, 2010; (iv) 6.25% on November 25, 2010; and (v) 6.25% on February 25, 2011.
[F3]This option was previously reported as covering 500,000 shares at an exercise price of $0.2 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
[F4]This option was previously reported as covering 55,556 shares at an exercise price of $1.08 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
[F5]The option vests in eight equal installments beginning May 12, 2011.
[F6]This option was previously reported as covering 50,848 shares at an exercise price of $1.18 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
[F7]The option vests as to one-eighth of the shares on June 28, 2011 and thereafter quarterly in seven equal installments beginning August 12, 2011.
[F8]The option vests quarterly in eight equal installments beginning on May 12, 2013.
[F9]Represents shares forfeited in satisfaction of exercise price of vested options.

Documents

1 file

GALECTIN THERAPEUTICS INC

CIK 0001133416

Entity typeoperating

IncorporatedNV